HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng, Jian Xu, Keun‐Wook Lee, Shunchang Jiao, Jorge León Chong, Roberto I. López-Sanchez, Timothy Jay Price, Oleg A. Gladkov, Oliver Stoß, Julie Hill · 2014

Read HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer by Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng, Jian Xu, Keun‐Wook Lee, Shunchang Jiao, Jorge León Chong, Roberto I. López-Sanchez, Timothy Jay Price, Oleg A. Gladkov, Oliver Stoß, Julie Hill (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w2136197678.txt.

Description

Eric Van Cutsem, Yung-Jue Bang, Feng-yi Feng, and colleagues published this study in Gastric Cancer in 2014. They report screening data from the ToGA trial, which tested the drug trastuzumab in stomach and gastroesophageal junction cancers. The drug targets tumors that make too much of a growth protein called HER2.

The trial holds the largest screening dataset on HER2 in this cancer type. Across screened patients, about twenty-two in a hundred tumors were HER2 positive. The authors link HER2 status with tumor subtype, location, region, and sample type. In the trial, adding trastuzumab to chemotherapy extended median survival, with the largest gains in tumors expressing the highest HER2 levels.

Catalog record

CREATOREric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng, Jian Xu, Keun‐Wook Lee, Shunchang Jiao, Jorge León Chong, Roberto I. López-Sanchez, Timothy Jay Price, Oleg A. Gladkov, Oliver Stoß, Julie Hill
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEOpenAlex / Gastric Cancer

Source: https://doi.org/10.1007/s10120-014-0402-y

Browse the full library · About the Tower of Babel